Oasis of Relief: Xerostom for Sjögren's Syndrome

Dry Mouth Relief: Can Xerostom® Products Really Help Sjögren's Syndrome?

Lena Voss monogram
Lena Voss in Health & Wellness October 2026 • 4 min read.

"A Randomized Clinical Trial Explores the Effectiveness of Xerostom® for Xerostomia in Primary Sjögren's Syndrome Patients."


Sjögren's Syndrome (pSS) is a chronic autoimmune disease primarily affecting moisture-producing glands, leading to dry mouth (xerostomia) and dry eyes. This condition significantly impacts the quality of life for many, particularly women in their 40s and 60s. The lack of saliva disrupts essential oral functions like speech, chewing, and swallowing, while also increasing the risk of dental problems such as cavities, periodontal disease and infections.

While there's no cure for Sjögren's Syndrome, various treatments aim to manage its symptoms. Common approaches include saliva substitutes, sugar-free gums, prescription sialogogues (saliva-stimulating drugs) like pilocarpine and cevimeline, and even systemic medications for more severe manifestations. However, these treatments often come with limitations and side effects, driving the need for more effective and tolerable options.

Xerostom® products, containing ingredients like olive oil, betaine, provitamin B5, allantoin, parsley oil, and xylitol, have shown promise in relieving dry mouth symptoms in individuals with polypharmacy-induced xerostomia and radiation-induced hyposalivation. A recent study investigated whether these products could also benefit patients with primary Sjögren's Syndrome, offering a potential avenue for managing this challenging symptom.

AI Search Multiple angles on this topic

Dry Mouth’s Daily Impact

The listed sources provide no prevalence figures or product-specific efficacy statistics. They report that oral symptoms are among the most distressing manifestations of Sjögren’s syndrome, and that dry mouth and reduced saliva can make speaking, chewing, and swallowing difficult. A 2023 study set out to examine the relationship between patients’ perceived oral dryness and discomfort and their use of specific interventions, noting that the use and efficacy of those interventions had only been partly evaluated.

Do Xerostom® Toothpaste and Mouthwash Alleviate Dry Mouth in Sjögren's Patients?

Oasis of Relief: Xerostom for Sjögren's Syndrome

A double-blind, randomized clinical trial was conducted to assess the effectiveness of Xerostom® toothpaste and mouthwash in primary Sjögren's Syndrome (pSS) patients experiencing xerostomia. The study involved 28 participants diagnosed with pSS according to the American-European Consensus Group (AECG) criteria. Participants were randomly assigned to either a test group using Xerostom® products or a control group using similar-looking placebos. Participants used the assigned products three times daily for 28 days. The study measured xerostomia using the Visual Analog Scale (VAS) and quality of life using the Oral Health Impact Profile-14 (OHIP-14) questionnaire.

While both groups experienced a decrease in VAS and OHIP-14 scores after the treatment period, no statistically significant differences were found between the two groups in the overall VAS scores. However, a significant improvement in OHIP-14 scores was identified in the test group, indicating an improved quality of life. Furthermore, a statistically significant difference was observed in the improvement of dry tongue sensation, with the Xerostom® group reporting greater relief.

  • Study Design: Double-blind, randomized, controlled trial.
  • Participants: 28 patients with primary Sjögren's Syndrome (pSS).
  • Intervention: Xerostom® toothpaste and mouthwash vs. control products.
  • Duration: 28 days.
  • Outcomes: Xerostomia (VAS) and quality of life (OHIP-14).
AI Search Multiple angles on this topic

Research on Symptom Relief and New Treatments

A 2024 review describes Sjögren’s syndrome as a chronic autoimmune disease affecting exocrine glands and potentially multiple organ systems; it says treatment has largely focused on symptom relief rather than the underlying autoimmune causes. A report on a meta-analysis of three clinical trials says Evoxac (cevimeline hydrochloride) significantly improved salivary flow and eased dry-mouth symptoms in people with Sjögren’s. A separate report on a small study says corticosteroid irrigation of major salivary glands significantly reduced objective and subjective dry-mouth measures, with greater benefits reported in patients with higher baseline symptom burden. These reports concern medical treatments, not evidence that Xerostom® products treat Sjögren’s itself.

Oral Risks When Saliva Is Reduced

The Sjögren’s Foundation explains that when saliva cannot neutralize acids in the mouth, those acids can break down tooth enamel. This highlights a potential oral-health consequence of dry mouth and why symptom relief alone may not address every concern. The supplied material also identifies the Cochrane risk-of-bias assessment tool as a method used to assess potential bias in clinical trials reviewed for dry-mouth treatments. It provides no specific trial results or product-level findings about Xerostom®.

Comparing Treatment Evidence

The listed sources point to different kinds of dry-mouth management evidence, but their supplied descriptions do not provide comparative outcomes. A 2018 article title identifies a double-blind, placebo-controlled multicenter trial of rebamipide for dry-mouth symptoms in people with Sjögren’s syndrome. The UpToDate listing describes a comprehensive guide focused on symptom relief and prevention of complications in dry mouth and other non-ocular sicca symptoms. The provided material does not establish how rebamipide compares with Xerostom® or other interventions.

The study suggests that Xerostom® toothpaste and mouthwash may provide some benefit in alleviating dry mouth symptoms and improving the quality of life for patients with primary Sjögren's Syndrome. The significant improvement in OHIP-14 scores in the test group, along with the relief of dry tongue sensation, indicates a potential positive effect of these products. However, the study also points out the importance of further research with a larger number of participants to confirm these findings.

The Future of Dry Mouth Treatments in Sjögren's Syndrome

The study provides valuable insights into the potential of Xerostom® products for managing dry mouth in Sjögren's Syndrome. While the results are promising, larger-scale studies are needed to confirm the efficacy and identify the specific patient subgroups who may benefit most from these topical treatments. Further research could also explore the long-term effects of Xerostom® and compare its effectiveness against other common dry mouth therapies. In the meantime, Xerostom® represents a safe and potentially helpful option for individuals seeking relief from the discomfort and challenges of xerostomia associated with Sjögren's Syndrome.

AI Search Multiple angles on this topic

What the Intervention Review Examined

A systematic review with meta-analysis examined interventions for dry-mouth symptoms and hyposalivation in Sjögren’s syndrome. The authors searched MEDLINE, Cochrane Central, and EMBASE for randomized trials published up to February 2018. The primary outcome was mean change in xerostomia symptoms, while hyposalivation was also included among the review’s outcomes. The supplied abstract does not report the review’s results, so it cannot support a conclusion about which intervention works best.

Toward More Targeted Treatments

A 2024 review says treatment options for Sjögren’s have largely focused on relieving symptoms rather than addressing underlying autoimmune causes, and describes personalized medicine as a direction for change. A 2025 news report describes work by University of Wisconsin doctors and faculty on a potential treatment: Dr. Sara McCoy partnered with the UW Program for Advanced Cell Therapy in 2022 to explore immunotherapy options for Sjögren’s-related dry mouth. The supplied report characterizes this as a potential treatment and does not establish that it is proven or available in routine care. The provided material does not link these research directions to Xerostom®.

Beyond Oral Symptoms

The supplied sources emphasize that Sjögren’s can involve more than the mouth and eyes. One source names the kidneys, liver, and hematologic systems as among the organ systems that may be affected, adding that this broader impact can make diagnosis and treatment more complex. The Sjögren’s Foundation also notes that people with the disease commonly have other diseases or health conditions that can pose challenges for diagnosis and treatment. A 2016 Sjögren’s Foundation survey analyzed 2,961 eligible responses to examine associations between oral and systemic manifestations and quality of life.

Dry Mouth in Daily Life

A 2021 paper describes dry mouth as a significant condition affecting the daily lives of people with Sjögren’s syndrome. Earlier qualitative research found that dry mouth can have a debilitating impact across functional and psychosocial aspects of well-being, while noting that qualitative studies of dry mouth and Sjögren’s were scarce. A 2025 real-world study reports a multifaceted burden on daily activities and health-related quality of life among adults with Sjögren’s, including high presenteeism and substantial impairment while working. These sources describe lived impact but do not report Xerostom® product outcomes.

What the dry-mouth evidence can establish

Dry-mouth sensation does not map neatly to saliva quantity alone: it may reflect reduced production or a change in saliva composition, and it can occur even when production is normal. This means symptom reports and saliva measurements may capture different aspects of the problem.[1] [2]

The reviews’ conclusions caution against treating the existence of many trials as proof that topical products reliably relieve dry mouth. Their findings point to uncertainty about effectiveness, not a demonstration that every product is ineffective.[1] [3]

How Xerostom fits beside other topical approaches

Earlier research tested saliva substitutes in Sjögren’s, including a double-blind comparison with glycerine mouthwash and a crossover comparison of carboxymethylcellulose- and mucin-containing substitutes. These designs show that topical approaches have been examined in this condition, but they do not establish how those products compare with Xerostom.[4] [5]

The Cochrane review reported that just one included trial was at low risk of bias, while 17 were at high risk. Its conclusion was that the review did not provide strong evidence for topical therapies as a class; another review also noted broad product variation and high risk of bias. This wider evidence base makes it difficult to infer a dependable class effect from one product trial.[1] [3]

What evidence would clarify dry-mouth relief

  • Do patient-reported dryness and measures of saliva production or composition change together, or do they capture distinct effects of treatment?[1] [2]

Sources

  1. Interventions for the management of dry mouth: topical therapies | Cochrane (www.cochrane.org)
  2. Significance and Implications of Patient-reported Xerostomia in Sjögren's Syndrome: Findings From the National Institutes of Health Cohort. (pubmed.ncbi.nlm.nih.gov)
  3. Efficacy of Artificial Salivary Substitutes in Treatment of Xerostomia: A Systematic Review (pmc.ncbi.nlm.nih.gov)
  4. Treatment of xerostomia: a double-blind trial in 108 patients with Sjögren's syndrome. (pubmed.ncbi.nlm.nih.gov)
  5. A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Sjögren's Syndrome, and how does it specifically relate to dry mouth?

Sjögren's Syndrome (pSS) is a chronic autoimmune condition that primarily affects moisture-producing glands, leading to symptoms like dry mouth (xerostomia) and dry eyes. This systemic disease can significantly impair oral functions such as speaking, chewing, and swallowing, and it elevates the risk of dental issues like cavities, periodontal disease, and infections. The disease is diagnosed using the American-European Consensus Group (AECG) criteria.

2

What are Xerostom® products, and what ingredients do they contain that are designed to combat dry mouth?

Xerostom® products contain ingredients like olive oil, betaine, provitamin B5, allantoin, parsley oil, and xylitol. These ingredients are intended to alleviate dry mouth symptoms. A clinical trial investigated the effectiveness of Xerostom® toothpaste and mouthwash in alleviating xerostomia related to primary Sjögren's Syndrome.

3

In the clinical trial using Xerostom® for Sjögren's patients, what specific improvements were observed in the group using Xerostom® toothpaste and mouthwash compared to the control group?

The study revealed that while both the Xerostom® group and the control group showed improvement in xerostomia (measured by the Visual Analog Scale or VAS) and quality of life (measured by the Oral Health Impact Profile-14 or OHIP-14), the Xerostom® group reported a statistically significant improvement in OHIP-14 scores, indicating an improved quality of life. Furthermore, a statistically significant difference was observed in the improvement of dry tongue sensation within the Xerostom® group.

4

What are the next steps in researching dry mouth treatments, particularly concerning products like Xerostom® and their application for Sjögren's Syndrome?

While the study suggests potential benefits of Xerostom® toothpaste and mouthwash for managing dry mouth symptoms in Sjögren's Syndrome, it also highlights the necessity for larger-scale studies to validate these findings. Future research could explore the long-term effects of Xerostom®, compare its efficacy against other dry mouth treatments, and identify specific patient subgroups who may benefit most. Additional research might explore different dosages and combinations with existing treatments like pilocarpine or cevimeline.

5

Besides products like Xerostom®, what are the typical treatments for dry mouth associated with Sjögren's Syndrome, and what are their limitations?

Common treatments include saliva substitutes, sugar-free gums, and prescription sialogogues like pilocarpine and cevimeline. Systemic medications are sometimes used for more severe manifestations. However, these treatments often have limitations and side effects, hence the need for more effective and tolerable options like Xerostom®.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.